As treatment with DABK was shown to increase the number of CD8+ T cells in the metastatic lungs, we hypothesize that activation of B1 receptor by DABK could be playing a role in promoting an increase of the immune response against the tumor. This evidence concerns the gene CD8A and neoplasm.